Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03848390
Other study ID # HSC-MS-18-1022
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 1, 2019
Est. completion date April 30, 2020

Study information

Verified date March 2019
Source The University of Texas Health Science Center, Houston
Contact Essam M Imseis, MD
Phone 713-500-5663
Email essam.imseis@uth.tmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to examine the effects of modified time-restricted feeding and conventional dietary approaches in motivated obese fatty liver patients on biochemical markers, imaging studies, and anthropometric measurements.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date April 30, 2020
Est. primary completion date April 30, 2020
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria:

- Motivated obese fatty liver patients aged 8 -18yrs with ALT >80

Exclusion Criteria:

- Patients with metabolic disorders,

- On certain medications (i.e., amiodarone, corticosteroids, methotrexate, select antipsychotics /antidepressants, HAART, valproic acid),

- Kwashiorkor

- Alcohol abuse,

- Rapid surgical weight loss,

- History of parenteral nutrition and

- Hepatitis C.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Conventional diet
The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
Modified Time-restricted Feeding
The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
Physical activity
At least 30 minutes of physical activity per day 5 times per week.
Restricted consumption of sweetened beverages
Restricted consumption of juice, soda, and other sweetened beverages.

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Alanine Amino Transferase (ALT) levels Baseline, 3 months
Secondary Change in Body Mass Index (BMI) Z-score Baseline, 3 months
Secondary Change in hepatic steatosis on Magnetic Resonance Elastography of the Liver Baseline, 3 months
Secondary Change in fibrosis on Magnetic Resonance Elastography of the Liver Baseline, 3 months
Secondary Change in diastolic blood pressure Baseline, 3 months
Secondary Change in systolic blood pressure Baseline, 3 months
Secondary Change in LDL Baseline, 3 months
Secondary Change in HDL Baseline, 3 months
Secondary Change in TRIGLYCERIDE Baseline, 3 months
Secondary Change in TOTAL CHOLESTEROL Baseline, 3 months
Secondary Hemoglobin A1C Baseline; 3 months
Secondary Fasting serum insulin Baseline; 3 months
Secondary Fasting serum glucose Baseline; 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4